SUMMARY
The effect of gut microbiota on obesity and insulin resistance is now recognized but the underlying host-dependent mechanisms remain poorly undefined. We found that Tissue Inhibitor of Metalloproteinase 3 knockout (Timp3-/-) mice fed a high-fat diet exhibit gut microbiota dysbiosis, an increase in branched chain and aromatic (BCAA) metabolites, liver steatosis and an increase in circulating soluble IL6 receptor (sIL6R). The sIL6R could then activate inflammatory cells such as CD11c+ cells to drive metabolic inflammation. Depleting the microbiota through antibiotic treatment significantly improved glucose tolerance, hepatic steatosis and systemic inflammation while neutralizing sIL6R signaling reduced inflammation but only mildly impacting glucose tolerance. Collectively, our results suggest that the gut microbiota are the primary drivers of the observed metabolic dysfunction and that this is mediated in part through IL-6 signaling. Our findings also identify an important role for Timp3 in mediating the effect of the microbiota in metabolic diseases.
INTRODUCTION
The prevalence of obesity and its metabolic sequels, including Type 2 Diabetes Mellitus, Non Lactobacillaceae/Lactobacillus (Tables S4-6 ). The first two were also evident when comparing WT 153 and Timp3-/-mice fed ND (Table S7, 8) .
154
To investigate whether gut microbiota contribute to the inflammatory and diabetic phenotype 155 observed in Timp3-/-mice and to test the relevance of our findings in a clinical perspective, we 156 performed two different treatments in both WT HFD and Timp3-/-HFD mice.
157
In the first approach, we modulated the microbiota in WT HFD and Timp3-/-HFD littermates using Figure S7A ). Remarkably, the BCKDH subunits mRNA expression was significantly 166 improved in Timp3-/-HFD liver and colon after Abx treatment ( Figure 5F ,G).
167
Next, we looked for agents that could translate the effect of dysbiosis at systemic level. IL-6 was 168 the most significantly increased cytokine in Timp3-/-HFD ( Figure S2C ) and loss of Timp3 may 169 potentially increase, via Adam17, the soluble form of the IL6 receptor (sIL6R) from liver and other 170 tissues (Scheller et al., 2014; Schumacher et al., 2015; Yan et al., 2015) . Our results confirmed that 171 Timp3-/-HFD showed significant increased levels of IL-6, sIL6R and IL-6/sIL-6R interaction in 172 serum ( Figure 6A ) as well as significantly increased levels of IL-6 in liver and WAT ( Figure 6B ).
173
Therefore, in the second approach we tested the hypothesis that dysbiosis in Timp3-/-mice was 174 responsible for the increase of the IL6/IL6R complex and in turn for myeloid cells trafficking.
175
When IL-6 binds to its soluble receptor, a trans-signaling alternative pathway is engaged, recruiting 176 proinflammatory cells and amplifying the inflammatory cascade in several diseases (Scheller et al., First, we investigated the levels of both IL-6 and soluble IL6Ralpha in serum sample of Timp3-/-179 and WT HFD subjected to antibiotic treatment compared with untreated samples.
180
We found decreased expression of both, the soluble IL6R and IL-6, in treated compared with 181 untreated samples serum from Timp3-/-HFD while no change was observed in the WT serum 182 samples (untreated versus treated) ( Figure 6C,D) . Similar results were observed in analysis of
183

CD11c
+ circulating cells in blood and SVC derived from WAT ( Figure 6E ) with decrease by Abx in Timp3-/-mice compared to untreated Timp3-/-mice ( Figure 7A and B, respectively).
194
In Timp3-/-treated with sgp130Fc we found a decreased number of circulating CD11c + cells and 195 several proinflammatory subpopulations in the blood at 1 month and in SVC at 2 months from 196 injection, while no differences were observed in blood at 2 months from injection either in Timp3-/- Figure S7B ).
DISCUSSION
We have identified a pathway coordinated by Timp3 that is active at the gut level. Gut dysbiosis in
201
Timp3 null mice leads to liver steatosis and the release of soluble IL6R. In turn, increased sIL6R 202 result s in accumulation of CD11c + cells in peripheral tissues and insulin resistance.
203
Data from other models clearly showed that activation of inflammatory pathways at gut level has a 204 broad role on glucose homeostasis at systemic level (Cox et al., 2015; Denou et al., 2015; Duca et 205 al., 2014; Everard et al., 2013; Tremaroli and Backhed, 2012) . The mechanistic role of intestinal 206 immune system as a primary sensor in the cross-talk between nutrients, gut microbes and host in 207 metabolic disorders has been recently identified (Everard et al., 2014) .
208
In previous analysis we showed that interaction of Kraakman et al., 2015) . Our data help to fill these gaps.
218
We show that sIL6R is higher in concomitance of the loss of Timp3. dysbiosis and BCAA metabolism, particularly in the colon itself and in the liver.
254
The gut microbiota is now accepted as a major component in metabolic disorders independently 255 from genetics, as well as a plausible cause to explain how social changes in only one century has so 256 dramatically increased the prevalence of obesity and related complications (Ridaura et al., 2013) .
257
Knowledge of gut microbiome is still poor although recent studies have identified some bacterial 258 genus and species that are causally linked to the onset of obesity and diabetes.
259
We have previously shown that Timp3 mice suffer from increased susceptibility to Inflammatory abnormalities independently of Timp3. To discern between these possibilities future studies must be 276 performed to address whether dysbiotic microbiota transplantation from Timp3-/-to WT mice is 277 sufficient to induce phenotype in WT mice, eventually using co-housing approach.
278
Our data suggest that beside the paradigm of bacterial translocation as an essential step for 279 development of obesity and its sequels, an alternative model characterized by metabolically active 280 dysbiosis exists and should be exploited in human subjects with diabetes.
281
In conclusion, we observed that Timp3 affects gut microbiome-related liver steatosis and glucose 282 intolerance in mice challenged with nutrient excess, suggesting that modulation of the gut 283 microbiome via Timp3 is a new possible mechanism to improve glucose intolerance status.
EXPERIMENTAL PROCEDURES
Mouse model and metabolic tests 285
Timp3-/-mice on a C57/BL6 background and metabolic testing procedures have previously been 286 described (Federici et al., 2005; Menghini et al., 2009; Mohammed et al., 2004; Serino et al., 2007) .
287
All animals procedures were in accordance with the Guide for the Care The caecal content was collected postmortem from each mice (5/group) and was stored at -80°C.
355
The DNA was extracted from the caecal content of mice using QIAamp DNA stool mini kit
356
(Qiagen, Venlo, Netherless) according to the manufacturer's instructions.
357
Microbial community composition was assessed by sequencing Hypervariable Regions HVR 5-6 of 358 the 16S ribosomal RNA (rRna) (GENOMNIA, EBI metagenomics accession number PRJEB8244)
359
derived from caecal samples of both chow diet (ND) and high fat diet (HFD) animals.
360
Antibiotics treatment
361
After 4 months on high-fat diet (HFD), WT and Timp3-/-mice were subjected to antibiotics 362 treatment. Norfloxacin, Metronidazole and Ampicillin (1 g/L each) (Sigma Aldrich) were added to 363 the drinking water for 4 week as described (Denou et al., 2015) . Yan, I., Schwarz, J., Lucke, K., Schumacher, N., Schumacher, V., Schmidt, S., Rabe, B., Saftig, P., 
